Stockreport

BioRestorative Granted Type B Meeting with FDA to Discuss Accelerated BLA Approval Pathway for BRTX-100 in Chronic Lumbar Disc Disease

BioRestorative Therapies, Inc.  (BRTX) 
NASDAQ:AMEX Investor Relations: biorestorative.com/content/investor-relations
PDF MELVILLE, N.Y., Nov. 17, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine inn [Read more]